slides · global inventory
Paragraph
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 118,471
Current window 34,771-34,800
Pages 3,950
Rows per page 30
Component
34,771-34,800 of 118,471
22
The slide uses a direct quote from a medical paper to expose the ineffectiveness of the company's recommended treatment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
23
The slide uses direct quotes from a KOL to build a case against the safety of a drug (Vykat) in the context of PWS.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
33
Uses a CEO quote to highlight a potential contradiction between management narrative and market reality.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
34
The slide uses a screenshot of a Soleno clinical trial flow diagram to highlight patient drop-off.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
45
The slide uses strong, accusatory language ('hoax', 'scientifically unfounded', 'misleading') to attack the target company's scientific rationale.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
111
The slide uses a combination of narrative summary and a Q&A transcript excerpt to build a case against the company's clinical trial transparency.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
134
The slide uses a direct quote and an abstract excerpt to build credibility for the argument that GH therapy has negative metabolic consequences.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
135
The slide uses direct excerpts from the FDA label to contrast with the company's reported clinical findings.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
136
The slide uses a 'two-hit' metaphor to describe the synergistic risk of the two medications.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
139
The slide uses a combination of a table excerpt and a text excerpt to highlight a specific reporting discrepancy.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
155
The slide uses Q&A transcripts to expose the risks associated with the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
186
The slide uses a Q&A format to present evidence of potential trial manipulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
187
The slide uses a Q&A format to highlight potential data manipulation or questionable internal confidence in clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
189
The slide uses a Q&A format to present qualitative evidence of investigator misconduct.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
208
The slide uses a line chart to visually debunk a competitor's claim about drug absorption kinetics.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
214
The slide uses molecular weight calculations to expose that DCCR is simply a salt form of diazoxide, implying the price premium is unjustified.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
218
Uses FDA label excerpts to highlight the contradiction between the drug's design and its actual usage/safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
221
The slide uses a Q&A transcript format to build a case against the drug's physical formulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
231
The slide uses a Q&A transcript format to highlight potential safety data suppression.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
246
The slide uses a Q&A format to present expert testimony.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
247
The slide uses a Q&A transcript format to build a case against the safety of the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
250
The slide uses direct quotes from a KOL to undermine the credibility of the clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
256
The slide uses direct quotes from a KOL to frame the company's town hall as an 'infomercial' that avoids difficult questions.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
270
The slide uses highlighted text to emphasize key parts of the expert interview transcript.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
274
The slide uses a Q&A transcript format to undermine the commercial viability of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
276
The slide uses a Q&A format to highlight the tension between corporate marketing pressure and scientific/ethical boundaries.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
282
The slide uses highlighted text to draw attention to key negative sentiments from the KOL.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
283
The slide uses direct quotes from a KOL to build a case against the safety profile of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
286
The slide uses highlighted text to emphasize key concerns about cardiac risk, genetic subtypes, and the drug's unknown mechanism of action.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
291
Uses direct quotes from a trial investigator to undermine the validity of clinical trial data.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits